Intervacc AB Logo

Intervacc AB

Develops recombinant protein vaccines and diagnostics for animal health, like Strangvac® for horses.

IVACC | ST

Overview

Corporate Details

ISIN(s):
SE0009607252 (+1 more)
LEI:
549300OICIVZBBZRNZ64
Country:
Sweden
Address:
Västertorpsvägen 135B, 129 44 Hägersten
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Intervacc AB is a biotechnology company that develops a new generation of vaccines for animal health. The company utilizes a modern technology platform based on recombinant protein fusions, stemming from research at the Karolinska Institutet and the Swedish University of Agricultural Sciences. Its lead product is Strangvac®, a vaccine against equine strangles. Through its subsidiary Nordvacc, Intervacc has an established sales organization with over 30 years of experience in the European animal health market. Another subsidiary, Mybac-Vettech, provides diagnostic laboratory services. The company's vaccines aim to strengthen animal health and wellbeing while contributing to the reduction of antibiotic use and combating antimicrobial resistance.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Intervacc AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Intervacc AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-02-26 Lennart Johansson Other Other 813,474 691,452.90 SEK
2025-02-21 Lennart Johansson Other Other 324,156 275,532.60 SEK

Peer Companies

Company Country Ticker View
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea 179530
Advicenne Logo
Develops and commercializes therapies for rare renal diseases for patients of all ages.
France ALDVI
AegirBio AB Logo
Develops user-friendly, saliva-based tests for health monitoring & therapeutic drug monitoring.
Sweden AEGIR
Aelis Farma Logo
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
France AELIS
AFC-HD AMS Life Science Co.,Ltd. Logo
An OEM of health foods, supplements, and cosmetics, managing the full value chain from R&D to sales.
Japan 2927
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark ALK
Alkaloid AD Logo
Manufactures pharmaceuticals, cosmetics, and herbal products for professionals and consumers.
North Macedonia ALK
ALLERGY THERAPEUTICS PLC Logo
Develops innovative, aluminum-free allergy immunotherapy vaccines for the European market.
United Kingdom AGY
Alligator Bioscience Logo
Develops immuno-oncology antibody drugs to activate the immune system against hard-to-treat cancers.
Sweden ATORX

Talk to a Data Expert

Have a question? We'll get back to you promptly.